NURS 615-PHARM EXAM 4 QUESTIONS AND ANSWERS

615-PHARM EXAM 4 “WE GOT NO MORE” Q&A SUMMER 2021 615-Pharm Exam 4 “We Got No More” Q&A 2021 ___ 1. Digoxin levels need to be monitored closely when the following medication is started: 1 . Loratadine 2 . Diphenhydramine 3 . Ipratropium 4 . Albuterol Albuterol ____ 2. Patients with pheochromocytoma should avoid which of the following classes of drugs because of the possibility of developing hypertensive crisis? 1 . Expectorants 2 . Beta-2-agonists 3 . Antitussives 4 . Antihistamines Beta 2-agonists ____ 3. Stan, a 42-year-old African American, has moderate persistent asthma. Which of the following asthma medications should be used cautiously, if at all? 1 . Betamethasone, an inhaled corticosteroid 2 . Salmeterol, an inhaled long-acting beta-agonist 3 . Albuterol, a short-acting beta-agonist 4 . Montelukast, a leukotriene modifier Salmeterol, an inhaled long-acting beta-agonist ____ 4. Long-acting beta-agonists (LTBAs) received a Black Box Warning from the U.S. Food and Drug Administration due to the: 1 . Risk of life-threatening dermatological reactions 2 Increased incidence of cardiac events when LTBAs are used 1 615-PHARM EXAM 4 “WE GOT NO MORE” Q&A SUMMER 2017 . 3 . Increased risk of asthma-related deaths when LTBAs are used 4 . Risk for life-threatening alterations in electrolytes Increased risk of asthma-related deaths when LTBAs are used ____ 5. The bronchodilator of choice for patients taking propranolol is: 1 . Albuterol 2 . Pirbuterol 3 . Formoterol 4 . Ipratropium Ipratropium ____ 6. Mathew is a 52-year-old overweight smoker taking t